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HIV MEDICATIONS AND BODY FAT
OBJECTIVES
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commonly associated with HIV infection and some of the
strategies related to treating these changes.
The learner will be able to discuss the newest antiretroviral
medications indicated for the treatment of HIV-1.
The learner will be able to explain the changes in the The US
Department of Health and Human Services newest guidelines
for the use of antiretroviral agents in HIV-1-infected adults and
adolescents.
Spotlight I:
Introducing the Newest Antiretroviral Medications
The purpose of this monograph is to
increase the knowledge of physi-
cians in correctional systems on
understanding management options
for viceral fat accumulation and
wasting - metabolic complications
associated with the use of some anti-
retrolviral therapies.
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The Case of the Progressively Prominent
Paunch
A 39-year-old man who has been incarcerated
for the last two years enters the clinic for a
return appointment. Leaning back against the
examination table he places both hands on his
abdomen and says, “Doc, how come my belly
got so big?” You eye the swell of his generous
midsection, laterally demarcated by the strain-
ing buttons of his prison-issue work shirt and
have to agree his midsection is growing. The
patient started a cocktail of HIV medications
eight months ago. His HIV viral load has fallen
to below the limit of detection for the assay and
his CD4 cell count has rebounded by over 100
cells. He has tolerated the medications and is
obviously adherent to his regimen. His weight
was 150 pounds when he entered prison and
quickly rose to 158 pounds with cessation of
crack cocaine and the availability of three
meals a day. Since starting HIV medications
his weight increased another 6 pounds. As a
well read HIV clinician, you look him in the eye
and shrug.
What causes HIV-therapy associated fat accu-
mulation remains a mystery. It has become
clearer that what was originally described as
‘crix-belly’ - after the protease inhibitor first
linked to this body shape change (indinavir) -
cannot be ascribed to any one antiretroviral or
even a HIV drug class. Studies of a variety of
antiretroviral regimens, including those con-
taining protease inhibitors (with or without
ritonavir) and non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs), have demon-
strated abdominal fat gains during therapy.1-4
Data from a large cohort of men with and with-
out HIV infection indicate that both groups
experience increases in waist circumference
over time - HIV therapy, however, accelerated
the growth of girth.5 Therefore, this undesir-
able pattern of fat gain during HIV therapy
seems to be associated not so much with par-
ticular HIV therapy per se, but with HIV thera-
py-mediated improvements in health.
Uncovering the mechanisms underlying the
preferential accumulation of deep visceral fat is
one of the great challenges in HIV therapeutics
research.
You say as much to your patient, his hands still
resting on his bulging middle. You explain that
switching his HIV medications to an alternative
seems imprudent as it is unclear that any new
combination would have a different effect on
belly fat. There are few data regarding the
effects of stopping HIV medications altogether
on fat accumulation but data from one study of
treatment interruptions indicates this is a haz-
ardous strategy in that those stopping treat-
ment experienced higher rates of bad things
happening to them including cardiovascular,
renal, hepatic and other adverse events.6
Unfortunately, studies of therapeutic interven-
tions for visceral fat accumulation have not
produced a treatment that can be resounding-
ly embraced. The best studies indicate that the
diabetes drug rosiglitazone does not work and
recent data raise concerns regarding the gen-
eral use of this drug.7 Pioglitazone has not
been well studied in the setting of HIV infec-
tion. Metformin may reduce waist size slightly
through unclear mechanisms but this effect
seems to be restricted to those with glucose
intolerance.7 Growth hormone does reduce
visceral fat but also reduces subcutaneous fat
and is extremely expensive, and at the doses
studied in HIV infected patients has been gen-
erally poorly tolerated.8 Of note, although
growth hormone has been found to have some
effect on visceral fat in clinical trials, such treat-
ment is outside of the approved indication of
this agent. Growth hormone releasing factor is
under study for HIV-associated fat accumula-
tion.9
An important consideration when confronted
with a protuberant midriff in a patient with HIV
infection is obesity. Not all big bellies are-
lipodystropy. Yet, it can be difficult to distin-
guish between visceral fat accumulation and
the increased subcutaneous abdominal fat
associated with excess caloric intake by phys-
ical examination alone. CT scanning or MRI
can distinguish between deep fat accumulation
and the more ubiquitous pinch-an-inch fat but,
while this information may be useful to the
patient concerned, and their abdominal girth
increase is an adverse effect of their medica-
tion, these are expensive tests and both can
respond to aerobic exercise and diet modifica-
tion - interventions that are cost-effective and
widely available.10
Certainly other causes of abdominal distension
should be considered, such as ascities. In
addition, a work-up for glucose intolerance pur-
sued with fasting glucose levels and two-hour
oral glucose tolerance testing. Those with glu-
cose intolerance and certainly diabetes melli-
tus may benefit from an oral hypoglycemic
such as pioglitazone or metformin or insulin in
terms of glycemic control and possibly visceral
fat volume. A fasting lipoprotein profile should
be ordered given the association between
body shape changes and dyslipidemia in per-
sons with HIV infection. In all cases a careful
dietary intake history needs to be conducted to
make certain canteen purchases are not dri-
ving fat gain and rigorous exercise advocated,
even if just fast walking, if possible.
Facing Fat Loss
For the next patient to arrive in clinic, fat gain is
not the problem. He is slender and on the mus-
cular side but his face looks slightly gaunt. The
naso-labial fold is more pronounced than
expected for a 34-year-old man while there is a
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Dear Correctional Colleagues,
Potent HIV treatments have rendered HIV infection a chronic condition for most of those living
with the virus in the U.S. A sign of the long term nature of HIV disease is the attention being
paid to cardiovascular and metabolic complications of HIV and its therapies. Within a little over
a decade, we have shifted much of our attention from the prevention of opportunistic infections
to prevention of heart disease, diabetes and the cancers that accompany aging. As an infec-
tious diseases specialist who turned away from a career in primary care, it is with some irony
that I find myself ordering lipid profiles, DEXA scans, glycosylated hemoglobin levels and
screening colonoscopies.
Within the constellation of metabolic problems one that is of particular concern to patients is
morphologic changes. Loss of fat in the face and arms or abnormal accumulation of fat in the
abdomen can be disfiguring and distressing to patients, threaten adherence to HIV medications
and risk disclosure of HIV status. Much remains to be learned about the causes of these vex-
ing body shape changes but it is becoming clearer that some of our original assumptions about
the etiologies of these complications were not correct. In this issue, two cases of body shape
changes in HIV-infected inmates are presented and discussed. The approaches taken in these
cases will, I hope, highlight the current thinking about the association between these changes
and HIV medications and approaches to their management.
Also in this issue is a brief overview of three of the newest medications to treat drug-resistant
HIV infection by Dr. Neil Fischer. These medications are particularly important to patients with
few remaining therapeutic options and appropriate application of these medications will go a
long way to preserving their activity.
Finally, this issue of IDCR is my last as Chief Editor. Serving as Chief Editor has been a won-
derful experience that has allowed me the opportunity to speak with many of you about the
issues we care about. Repeatedly, you have told my colleagues and I how much you appreci-
ate the newsletter and your comments have sustained me through late night re-writes and last
minute frenzies to get IDCR to you. I now hand the baton to my esteemed colleague Dr.
Joseph Bick. I can think of no steadier hand to guide IDCR into 2008 and beyond. It takes
a bunch of people to make IDCR possible. I wish to thank Elizabeth Closson, our Managing
Editor, for her tireless efforts to make the newsletter a success, Annie DeGroot for her leader-
ship, our thoughtful Editorial Board and, you, our readers for your profound commitment to the
care of your patients.
David A. Wohl, MD
Associate Professor of Medicine
Division of Infectious Diseases
AIDS Clinical Research Unit
The University of North Carolina - Chapel Hill
LETTER FROM THE EDITOR
HIV MEDICATIONS AND BODY FAT
P.S. New (2007) modified format on
first page is made to comply with the
ACCME requirements
hollowing at his temples. He has been incar-
cerated for six years and was diagnosed with
HIV on intake. He initiated zidovudine, lamivu-
dine and efavirenz and has successfully con-
tinued on that regimen since with excellent
virologic and immunologic responses. When
asked he says he has noticed that his face
appears thin and that sometimes people ask
him if he is sick. The muscles in his arms are
prominent but he thinks this is because he lifts
weights. His appetite is good and his weight
has been stable during his incarceration. He
smokes a pack of cigarettes a day.
Fat wasting of the limbs and face appears to
be more common than visceral fat accumula-
tion in HIV-infected persons.11 The loss of fat
can be subtle and go unnoticed. In correction-
al and community clinics few patients are
examined unclothed and, therefore, opportuni-
ties to observe changes in the thighs, buttocks
and upper arms – regions where fat loss may
be most pronounced – are missed. Facial fat
loss often prompts patients to raise this prob-
lem with their clinician and frequently it is when
facial thinning is mistaken by others for illness
that patients become concerned.
In this case you may have more to offer your
patient. As opposed to fat accumulation, wast-
ing of subcutaneous adipose tissue of the
limbs, face and abdomen has been directly
linked to specific HIV medications. Both the
thymidine analogues stavudine and zidovudine
have been found to be associated with limb fat
loss regardless of the companion drugs.12 A
recent AIDS Clinical Trials Group (ACTG) trial
that compared ritonavir-boosted lopinavir with
the NNRTI efavirenz in treatment na_ve
patients taking zidovudine, tenofovir or stavu-
dine plus lamivudine found that nucleoside
selection influenced fat loss.1 As expected
stavudine was the worst offender but zidovu-
dine also produced significant fat loss in the
limbs as measured by DEXA scans. Fat loss
during tenofovir based therapy was much less
common. Importantly and surprising to many
was that participants receiving efavirenz had
more fat loss than those on the protease
inhibitor, regardless of which nucleoside was
co-administered. A third study group that
received lopinavir/ritonavir plus efavirenz with-
out any nucleoside analogues experienced a
net gain of limb fat that continued during 96
weeks of study follow-up.
These data suggest that zidovudine can con-
tribute to fat loss, especially when taken with
efavirenz. In patients with signs of lipoatrophy
a switch in HIV treatment is justifiable. Data
from studies in which stavudine or zidovudine
were substituted with tenofovir or abacavir
demonstrated objective improvements in limb
fat following the switch.13-15 These improve-
ments, however, were modest, slow to accrue
and were not always appreciable to partici-
pants. However, switching did seem to pre-
vent subjective worsening of lipoatrophy.
Beside antiretroviral substitution there is little
else to offer patients with lipoatrophy. As in the
case of fat accumulation, the data on diabetes
drugs are not impressive. Androgens are
lipolytic and can make matters worse. The
nucleoside uridine is under study for HIV-asso-
ciated fat wasting. Reconstructive procedures
such as polylactic acid injection into the facial
subcutaneous tissue can improve appearance
but is unlikely to be available for incarcerated
patients.
You discuss the options with the patient,
explaining that his HIV medications may well
be responsible for the loss of fat in his face and
limbs and left on the current regimen his fat
loss can progress. You discuss the switch
options. He can move to a new regimen devoid
of both zidovudine and efavirenz. This will
require more pills and he is less than enthusi-
astic about such an approach. An alternative
he finds much more attractive is to change to
fixed dose tenofovir, emtricitabine, efavirenz –
which eliminates just the zidovudine. The
reduction in pill count sweetens this unexpect-
ed change in medication and he agrees to this
change. The above-mentioned ACTG study
found that only 12% of those taking tenofovir,
lamivudine and efavirenz experienced a 20%
or greater loss in limb fat during 96 weeks
compared to 40% of those who received
zidovudine with their lamivudine and
efavirenz.1
The patient is counseled regarding the poten-
tial adverse effects of his new regimen and
also encouraged to stop smoking as part of
preventive health. Fasting lipid levels are
obtained given the association between fat
changes and dyslipidemia and rechecked
eight weeks later. He tolerates the switch well
and during follow-up continued monitoring of
his lipoatrophy will be conducted.
Summary
These two cases present both sides of the
issue of body shape changes being seen dur-
ing HIV infection. But, perhaps the most com-
mon fat change in HIV-infected persons is gen-
eral obesity.16 Unique strategies to address
this common problem in HIV-infected patients
have not been studied and in their absence we
rely on the techniques developed for the gen-
eral population – exercise, caloric restriction
and dietary modification. One of the strongest
predictors of mortality in the developed world is
waist circumference and recognizing the
health risks attending obesity, including dys-
lipidemia and diabetes, is paramount in our
patients with HIV infection.
Fat changes that may be more specific to the
HIV-infected population than the general pop-
ulation - visceral fat accumulation and subcu-
taneous lipoatrophy - remain a challenge to
patients and their clinicians. For visceral fat
accumulation, there are frustratingly few thera-
peutic options above and beyond the standard
lifestyle interventions. Switching HIV medica-
tions has not been consistently demonstrated
to substantially change visceral adipose tissue
volume and treatment options are limited.
Growth hormone works but is impractical and
poorly tolerated. In the case of lipoatrophy,
substitution of thymidine analogues is a rea-
sonable approach to prevent worsening if not
reversal of subcutaneous fat loss.
Clearly, in both disorders, the gap in our under-
standing of the underlying pathogenesis is vast
and our ability to offer our patients answers, let
alone treatment, meager. Until we have the
answers we need, we must help our patients
and colleagues not fill the data vacuum with
perception and mistaken belief. Data from a
number of clinical trials have made the rela-
tionships between HIV therapies and body fat
changes clearer and have dispelled some of
the myths we had come to accept as fact. As
we learn more about the mysteries of fat
change during HIV treatment we need to also
learn to avoid assumption and leaps of faith.
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4SPOTLIGHT I: INTRODUCING THE NEWEST ANTIRETROVIRAL MEDICATIONS
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It was 20 years ago, in 1987, that zidovudine
(AZT) was approved for the treatment of HIV
infection. At that time, few could have imag-
ined that HIV/AIDS would now be managed
as a chronic disease. In 1987, few could
also have imagined, with more than 30
approved antiretrovirals, patients would har-
bor viruses with resistance to multiple anti-
retroviral agents. to multiple antiretroviral
medications. Drug resistance has made an
increasing number of HIV-infected patients
see their treatment options dwindle. Two
new Food and Drug Administration (FDA)-
approved medications, maraviroc and ralte-
gravir, are now available to manage patients
infected with highly resistant virus. A third
medication, etravirine, is under FDA review
for approval and a decision is expected in
January, 2008. These new medications are
profiled below.
Raltegravir, an integrase inhibitor, was
approved by the FDA in October, 2007 for
use in combination with other antiretroviral
agents for the treatment of treatment-expe-
rienced adult HIV-infected patients who
have evidence of ongoing viral replication
and HIV strains resistant to multiple anti-
retroviral agents. This is the first drug of a
completely new class of antiretrovirals, the
integrase inhibitors. By being in a novel
class, there is no known cross resistance
between raltegravir and other presently
available agents. Integrase inhibitors work
at blocking HIV integrase, an enzyme that
plays an essential role in integrating the viral
DNA into the host cells’ chromosomes. The
approved dose of raltegravir is 400 mg (1
tablet) administered orally, twice daily, with
or without food. Raltegravir was studied in
two identical international studies of heavily
antiretroviral-experienced patients.
Participants were randomized to raltegravir
or placebo along with an optimized back-
ground of antiretrovirals selected by the par-
ticipant’s clinician. These trials demonstrat-
ed significantly better virologic and immuno-
logic outcomes over 24 weeks of study for
those assigned to raltegravir. Importantly,
the benefit of raltegravir was enhanced
when one or more other active agents (such
as darunavir and/or enfuvirtide) were also
included in the antiretroviral mix. The med-
ication was generally well tolerated in these
clinical trials. The most common adverse
reactions observed were nausea,
headache, diarrhea and pyrexia; there were
no major differences in the rate of these
complications between those assigned the
drug or placebo arms of the study. Creatine
phosphokinase elevations were observed in
some patients receiving raltegravir and it is
suggested the drug be used with caution in
patients at increased risk of myopathy or
rhabdomyolysis, such as those also receiv-
ing statins. As with many other antiretroviral
medications, administration with rifampin
reduced the concentration of raltegravir.
Elvitegravir, another integrase inhibitor, is in
phase IIb clinical development. Available
data suggest that there is cross resistance
between these two integrase inhibitors.
Maraviroc, an entry inhibitor, was approved
by the FDA in August, 2007 for use in
patients with multidrug-resistant CCR5-trop-
ic virus who have evidence of viral replica-
tion. Vicriviroc, another CCR5 antagonist is
in phase III of development. These drugs
are also part of a completely new class of
antiretroviral medications. CCR5 antago-
nists are different from other currently avail-
able oral HIV/AIDS antiretroviral drugs,
which work by inhibiting HIV replication
intracellularly. CCR5 antagonists work at
obstructing the entry of HIV into the CD4
cell. Entry of HIV into the host CD4 cell
requires binding not only to the CD4 recep-
tor but also to either CCR5 or CXCR4 co-
receptors. Blocking of these co-receptors
inhibits viral entry into the cell. Maraviroc
and vicriviroc, as CCR5 antagonists, only
have activity against virus that uses exclu-
sively CCR5 receptors. Virus that exhibit
CXCR4 tropism will not be inhibited by these
drugs. Therefore, assessing viral tropism
prior to use of this call of drugs is a neces-
sary. Presently there is one commercially
available tropism assay with a cost of
approximately $2000. The assay will deter-
mine if the HIV virus is expressing CCR5
tropism or CXCR4 tropism or a dual or
mixed (D/M) tropism. Several studies have
been done to determine expected tropism.
In treatment na_ve patients, the majority of
patients are expected to have CCR5 tropic
virus. Nevertheless, even among treatment-
na_ve patients 12-19% had detectable D/M
or CXCR4 virus and these patients are more
likely to have lower CD4 cell counts.
Patients with more advanced HIV disease
would be expected to have much higher
rates of CXCR4 tropic virus. In the two
major trials leading to the approval of mar-
aviroc – studies of the drug versus placebo
in patients with extensive antiretroviral expe-
rience - approximately half the patients
screened had evidence of D/M or CXCR4
tropic virus and were not eligible for study
entry. Therefore, among patients with low
CD4 cell counts and multidrug resistant
virus it can be expected that maraviroc
would be inappropriate for use in about half.
Hepatotoxicity has been reported with mar-
aviroc use and may be associated with a
systemic allergic reaction. The use of this
new medication has not been specifically
studied in patients with significant underly-
ing liver disorders including hepatitis B virus
or hepatitis C virus infections. Therefore
caution should be used in using maraviroc
with patients with liver disorders. As is the
case with all new antiretroviral agents, mar-
aviroc needs to be given with other active
antiretrovirals to maintain antiviral effect. If
given with a protease inhibitor (except
tipranavir/ritonavir) the dose is 150 mg (1
tab) orally twice daily. If given with
tipranavir/ritonavir or nevirapine the dose is
300 mg twice daily.
Etravirine (TMC-125), is a “second genera-
tion non-nucleoside reverse transcriptase
inhibitor (NNRTI).” This medication is not
yet FDA approved. The medication was
selected for development for its activity
against wild-type and NNRTI-resistant virus.
In contrast to the NNRTIs, nevirapine and
efavirenz, etravirine requires multiple
NNRTI mutations before a significant loss of
susceptibility is observed. Etravirine has
been shown to be active even when the
NNRTI resistance mutation K103N is pre-
sent. Therefore, this medication may be
useful in patients who harbor virus that
developed resistance to efavirenz or nevi-
rapine. The dose going forward for approval
is two 100 mg tablets orally twice daily.
Etravirine, in clinical studies, has been
shown to augment the effect of ritonavir-
boosted darunavir in patients with prior
NNRTI treatment and is the first NNRTI to
show clinical efficacy over 24 weeks, after
previous nevirapine or efavirenz failure. The
drug was generally well tolerated and safe.
Rashes occurring with etravirine were gen-
erally early in onset, mild to moderate in
severity and lasted less than a week on
average. The incidence of rash was less
than that cited with efavirenz. There was no
mucosal or hepatic involvement or Stevens-
Johnson syndrome in patients treated with
etravirine. Central nervous system (CNS)
toxicity is not expected to be an issue for this
agent. Another medication in the second
generation NNRTI pipeline is TMC-278. This
agent is entering into a large scale clinical
study where it will be dosed once daily.
Summary
As highlighted above, these individual
agents can be potent additions to the HIV
pharmacopoeia. It is essential to recognize
that each trial of these agents has shown
the importance of having at least two fully
active drugs in a new regimen; as combina-
tions of active agents are essential for viro-
logic response and to forestall drug resis-
tance. The ability to have the highly treat-
ment-experienced patients obtain the goal
of undetectable levels of virus has been
improved by the development of these new
medications and medication classes. As
with any new medications, familiarization
with the package insert prior to prescribing
these medications is important.
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"Genotypic resistance testing should be performed for all treatment-naïve patients entering into care,
regardless of whether ARV therapy is to be initiated (AIII). This recommendation is based on the fact
that transmitted resistance mutation may be detected at a time point more proximal to the time of infection
than later. Repeat testing may be considered at the time when therapy is to be initiated (CIII)."
"Tropism testing should be peformed prior to the initiation of a CCR5 antagonist,
such as maraviroc (AII). Coreceptor tropism testing might also be considered for patients
exhibiting virolgic failure on maraviroc (or any CCR5 inhibitor) (BIII). "
HLA-B*5701 testing should be intiated prior to initiating abacavir therapy to reduce the
risk of hypersensitivity reaction (AI). HLA-B*5701-positive patients should not be prescribed
abacavir (AI), and the positive status should be recorded as an abacavir allergy in the patient's
medical record (AII). When HLA-B*5701 testing is not readily available, it remains reasonable to
initiate ABC with appropriate clinical counselling and monoriting for any signs of abacavir-associated
hypersensitivity reaction (CIII).
ARV therapy should be initiated in patients with history of an AIDS defining illness or with a CD4 T-cell count of <350 cells/mm3. The data sup-
porting this recommendation are stronger for those with a CD4 T-cell count <200 cells/mm3 and with a history of AIDS (AI) than for those with
CD4 T-cell counts between 200 and 350 cells/mm3 (AII).
Treatment for the following groups should be initiated regardless of CD4 T-cell count:
1. pregnant patients (AI)
2. patients with HIV associated nephropathy (AI)
3. patients co-infected with hepatitis B when treatment for hepatitis B virus is indicated (BIII)
The optimal time to initiate therapy in asymptomatic patients with CD4 T-cell count >350 cells/mm is not well defined.
The decision of whether or not to start therapy in these patients should take into account the potential benefits
and risks associated with therapy, comorbidities, and patient readiness and willingness to adhere to long-term treatment.
In treatment-experienced patients with suppressed viremia, assess adherence frequently and simplify the regimen
as much as possible. Change individual antiretroviral drugs to reduce or manage toxicity, as needed.
Adding at least two, and preferably three, fully active agents to an optimized background antiretroviral regimen
can provide significant antiretroviral activity (BII).
Immunologic failure can be defined as a failure to achieve and maintain an adequate CD4 response despite virologic suppression.
For immunologic failure, current medications, untreated coinfection, and serious medical conditions should be assessed.
There is no consensus for when and how to treat immunologic failure. Tolerated antiretroviral drugs were used.
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HIV 101: CHANGES IN THE GUIDELINES FOR THE USE OF ANTIRETROVIRAL
AGENTS IN HIV-1-INFECTED ADULTS AND ADOLESCENTS, DECEMBER 2007
Drug Resistance
Tropism Assay
HLA-B*5701 Testing
When to Initiate ARV Therapy
Management of the Treatment – Experienced Patient
Laboratory Assesment
Rating Scheme for Recommendations
Strength of Recommendation: A=Strong B=Moderate C=Optional D=Should usually not be offered E=Should never be offered
Quality of Evidence for Recommendation: I=At least one randomized trial with clinical results II:Clinical trials with laboratory results III:Expert opinion
Source: The US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. December 2007.
Available at http://aidsinfo.nih.gov/.
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Immune Status at Presentation to Care Did Not Improve among
Antiretroviral-na_ve Persons from 1990 to 2006
Researchers at the Johns Hopkins School of Medicine recently com-
pleted a longitudinal observational study of patients in primary HIV
care in HIV practices operated by the Johns Hopkins HIV service in
Maryland. The study included 3,348 antiretroviral-na_ve patients,
most of whom were black men, and lasted from January 1990
through June 2006. All participants were stratified into one of four
groups (1990-1994, 1995-1998, 1999-2002, and 2003-2006),
according to their year of enrollment at the clinic. This stratification
was used in order to better observe trends in HIV testing and treat-
ment over time. Researchers collected data regarding the amount of
time between initial HIV diagnosis and presentation for care for each
participant, as well as their CD4+ at the time of their presentation.
After determining the median absolute CD4+ cell count at presen-
tation and the number of days from when the person learned his HIV
serostatus to when he presented for care, the research team ana-
lyzed the entire sample by sex, race, and HIV transmission risk
group (injection drug user [IDU], men who have sex with men [MSM],
and heterosexual). Researchers found that the median age of par-
ticipants increased over time and that transmission risk also
changed over the course of the study. The portion of participants
with IDU transmission risk decreased over time, while greater het-
erosexual transmission was reported. Also, the median CD4+ count
at presentation decreased over calendar time, meaning that the first
strata (1990-1994) had a higher median than the most recent strata
(2003-2006). While the CD4+ count decreased over time in hetero-
sexual and IDU HIV transmission subgroups, this was not the case
in the MSM transmission subgroup. The MSM subgroup also
demonstrated the shortest interval between diagnosis and presenta-
tion; this interval decreased over time for white MSM.
The overall trend of lower median CD4+ cell counts at presentation
for patients in most transmission subgroups demonstrates that
patients in more recent years are presenting for care later in the
course of HIV-infection. Earlier identification of HIV-infection can
significantly improve the survival benefit of antiretroviral therapy and
can reduce morbidity. Furthermore, studies suggest that the initia-
tion of antiretroviral therapy can help reduce the further transmission
of HIV, thus reducing the spread of the virus to others. This study
only serves to emphasize the importance of implementing the CDC’s
recommendations for the increased routinization of HIV testing.
Keruly, J et al. Immune Status at presentation to Care Did Not
Improve among Antiretroviral-Na_ve Persons from 1990 to 2006.
Clinical Infectious Diseases. 2007;45:1369-74.
Fed’s Care for HIV Detainees Falls Short
The US Department of Homeland Security has failed to provide sat-
isfactory health care to HIV-positive immigrant detainees. A 71-
page report, put out by Human Wrights Watch, found that the lack of
sufficient health care for detainees was putting their health and their
lives at risk. The department’s guidelines for HIV care failed to meet
both the national and international standard of care. The report stat-
ed that without internal oversight and accountability to the public,
“immigrant detainees with HIV/AIDS will continue to needlessly suf-
fer, and in some cases die in US immigration detention.” There were
47 detainees infected with HIV in US Immigration and Customs
Enforcement (ICE) facilities through April 2007. According to the
report, detainees also are held in other facilities such as local jails
and regional centers, where the government does not track the num-
ber of people with HIV. When questioned about the Human Rights
Watch report, ICE spokeswoman Kelly Nantel said, “ICE provides
excellent care to the detainees in our custody…we spend nearly
$100 million every year on detainee health care.” According to Ms.
Nantel, approximately one quarter of the 300,000 people that ICE
processes each year are diagnosed with chronic health problems,
and many only learn about them during their incarceration. The
report requests that the government increase the number of facility
inspections, revise medical guidelines for detainee care, and
improve protection for lesbian, gay, bisexual, transgender, and HIV
positive detainees. The report also urges the government to
increase access to HIV testing.
Kearney, Christine and Cooney, Peter. “U.S. care for HIV detainees
falls short: report”. Reuters Online. 7 Dec. 2007.
CD4 Cell Count at Presentation for Clinical Care is Low and
Unchanged Since 1990
To examine trends in the time from HIV diagnosis to first presenta-
tion for HIV clinical care and initial CD4 cell count, researchers at the
Johns Hopkins School of Medicine studied the records of 3,348
patients who were antiretroviral-na_ve at the time of presentation to
their clinic from January 1990 through June 2006.
The median presenting CD4 cell count was 371 cells/uL during
1990-1994 but fell to 271 cells/uL by 2003-2006. The downward
trend in initial CD4 was observed in men and women, whites and
blacks, heterosexuals and injection drug users. Only among men
who have sex with men was there a reverse trend of increasing CD4
cell count at presentation. There was a decline in the median time
from HIV diagnosis to entry into HIV health care during the course of
the study period. During 1990-1994, the time from diagnosis to care
was 271 days and in 2003-2006 it was 196 days.
The overall trend of lower median CD4+ cell counts at presentation
for patients in most transmission subgroups demonstrates that
patients in more recent years are presenting for care later in the
course of HIV-infection. Earlier identification of HIV-infection can sig-
nificantly improve the survival benefit of antiretroviral therapy and
can reduce morbidity. Furthermore, studies suggest that the initia-
tion of antiretroviral therapy can help reduce the further transmission
of HIV, thus reducing the spread of the virus to others. This study
only serves, the authors conclude, to emphasize the importance of
implementing the CDC’s recommendations for the increased rou-
tinization of HIV testing.
Keruly, J et al. Immune Status at presentation to Care Did Not
Improve among Antiretroviral-Na_ve Persons from 1990 to 2006.
Clinical Infectious Diseases. 2007;45:1369-74.
Incarceration and Risky Sexual Partnerships in a Southern US
City
Although incarceration has often been associated with sexually
transmitted infections (STI) and HIV, just how incarceration impacts
risky sexual behavior has yet to be determined. To examine the role
of personal or partner incarceration on risk behavior researchers
from the University of North Carolina identified social venues with
high levels of new, multiple, and concurrent sexual partnerships in
an urban area in the US South where incarceration and HIV are both
endemic. This process of identifying social venues involved inter-
viewing community members about places in the city where people
meet new sexual partners. The research team then visited each
venue and conducted structured face-to-face interviews with random
individuals about their sexual behavior and substance use history.
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Department of Health and Human Services 2007 Adult and
Adolescent Antiretroviral Treatment Guidelines
http://aidsinfo.nih.gov/Guidelines/Default.aspx?MenuItem=Guidelines
National HIV/AIDS Clinician’s Consultation Center
Warmline: National HIV Telephone Consultation Services
1-800-933-3413
PEPline: National Clincian’s Post-Exposure Prophylaxis Hotline
1-888-448-4911
Perinatal Hotline: National Perinatal HIV Consultation and Referral
Services
1-888-448-8765
CDC's Revised Recommendations for HIV Testing of Adults,
Adolescents, and Pregnant Women in Health-Care Settings
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm
CDC’s National HIV Testing Resource Website
http://www.hivtest.org/
CDC’s Correctional Health Website
http://www.cdc.gov/correctionalhealth/
International AIDS Society-USA Panel
2006 Recommendations of the Treatment for Adult HIV Infection
http://jama.ama-assn.org/cgi/content/full/296/7/827
Center for Health Justice
http://healthjustice.net/
Community HIV/AIDS Mobilization Project
http://www.champnetwork.org/
American Correctional Health Services Organization
http://www.achsa.org/index.cfm
American Academy of HIV Medicine
http://www.aahivm.org/
RESOURCES
During the interview, each participant was asked if they had multiple
partnerships (having at least two new sexual partners in the past 4
weeks) and if they had engaged in transactional sex-- defined as giv-
ing or receiving money, goods, or services in exchange for sex-- in
the past four weeks. Interviewers also asked male participants if
they had been incarcerated for longer than twenty-four hours in the
past twelve months and asked women if they had ever been incar-
cerated for longer than twenty-four hours. In addition, participants
were asked if they had had a sexual partner in the past twelve
months who had ever been incarcerated for longer than twenty-four
hours.
Approximately two-thirds of the 373 participants (144 women and
229 men) were African American, one-third of participants reported
unemployment, and a significant portion of the participants had not
completed high school. Among men, approximately 21% reported
incarceration for longer than twenty-four hours in the past twelve
months and 17% had a sexual partner in the past twelve months who
had ever been incarcerated. This relationship was similar in women,
29% of whom reported ever being incarcerated for longer than twen-
ty-four hours and 18% had a sexual partner in the past twelve
months who had ever been
incarcerated.
Men who had been incarcerated in the past twelve months were four
times more likely to report transactional sex in the past four weeks
than men without recent incarceration history. Women who had ever
been incarcerated were three times more likely to have had multiple
new sexual partnerships in the past four weeks than women with no
incarceration history. Furthermore, adjustment for demographic and
socioeconomic confounding variables had little effect on these rela-
tionships.
This study supports the previously demonstrated relationships
between personal incarceration and risky sexual behavior, as well as
findings that incarceration of a recent partner is associated with risky
sexual partnerships. Moreover, the observation of a strong associ-
ation between incarceration history and sexual risk behaviors sup-
ports the need for STI/HIV prevention efforts targeting former pris-
oners and their partners.
Khan, M et al. Incarceration and Risky Sexual partnerships in a
Southern US City. Journal of Urban Health: Bulletin of the New York
Academy of Medicine.
Compiled by Christine Devore
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SELF-ASSESSMENT TEST FOR CONTINUING MEDICAL EDUCATION CREDIT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing
Medical Education through the joint sponsorship of Medical Education Collaborative, Inc. (MEC) and IDCR. MEC is accredited by the ACCME
to provide continuing medical education for physicians.
Medical Education Collaborative designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. The target audience
for this educational program is physcians. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Statements of credit will be mailed within 6 to 8 weeks following the program.
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In order to receive credit, participants must score at least a 70% on the post test and submit it along with the credit
application and evaluation form to the address/fax number indicated. Statements of credit will be mailed within 6-8 weeks
following the program.
Please print clearly as illegible applications will result in a delay.
Name: _________________________________________________ Profession: __________________________________
License #: ___________________________________ State of License: __________________________________________
Address: ____________________________________________________________________________________________
City: ________________________ State: ________ Zip: ________________________ Telephone: ___________________
Please check which credit you are requesting ___ ACCME or ___ Non Physicians
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
I certify that I participated in IDCR monograph December 2007 Issue
Please fill in the number of actual hours that you attended this activity.
Date of participation: ______________________
Number of Hours (max. 1): ___________________
Signature: _________________________________________________
Please Submit Completed Application to:
Medical Education Collaborative
651 Corporate Circle, Suite 104, Golden CO 80401
Phone: 303-420-3252 FAX: 303-420-3259
For questions regarding the accreditation of this activity, please call
303-420-3252
Instructions:
• Applications for credit will be accepted until
December 31, 2008.
• Late applications will not be accepted.
• Please anticipate 6-8 weeks to recieve your certificate.
Objectives:
The learner will be able to describe the body shape changes commonly associated with HIV infection and some of the strategies related to treating
these changes.
The learner will be able to discuss the newest antiretroviral medications indicated for the treatment of HIV-1.
The learner will be able to explain the changes in the The US Department of Health and Human Services newest guidelines for the use of
antiretroviral agents in HIV-1-infected adults and adolescents.
1. According to data from a large cohort of men with and without HIV
infection, the undesirable pattern of fat gain during HIV therapy seems to
be associated with particular HIV therapies and not so much with HIV
therapy-mediated improvements in health.
TRUE OR FALSE
2. Visceral fat accumulation and the increased subcutaneous abdominal
fat associated with excess caloric intake have which of the following in
common:
A. Metaformin is indicated for the reduction of both types.
B. Both types respond to aerobic exercise and dietary modification
C. Both types are an indication of lipodystrophy
D. Both A and C
3. Compared with visceral fat accumulation, wasting away of the limbs
and face:
A. Is more difficult to treat
B. Is more common than visceral fat accumulation
C. Is directly related to the HIV medications stavudine and
zidovudine
D. Both B and C
4. Which of the following is NOT true about Entravirine:
A. Entravirine is a second generation non-nucleoside reverse tran
scriptase inhibitor (NNRTI)
B. In clinical studies entravirine been shown to augment the effect of
ritonavir-boosted darunavir in patients with prior NNRTI treatment
C. Assessing viral co-receptor preference, so called viral tropism, is
a necessary step prior to use of etravirine.
D. There was no mucosal or hepatic involvement or Stevens-
Johnson syndrome in patients treated with etravirine.
5. According to the new 2007 DHHS guidelines for the use of antiretrovi-
ral agents in HIV-1-infected adolescents and adults, ARV therapy should
be initiated in patients with history of an AIDS defining illness or with a
CD4 T-cell count of <350 cells/mm3.
TRUE OR FALSE
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COURSE EVALUATION
I. Please evaluate this educational activity by checking the appropriate box:
Activity Evaluation
Faculty
Content
How well did this activity avoid com-
mercial bias and present content that
was fair and balanced?
What is the likelihood you will
change the way you practice based
on what you learned in this activity?
Overall, how would you rate
this activity?
Excellent Very Good Good Fair Poor
II. Course Objectives
Were the following overall course objectives met? At the conclusion of this presentation, are you able to:
III. Additional Questions
a. Suggested topics and/or speakers you would like for future activities.
b. Additional Comments
YES NO SOMEWHAT
YES NO SOMEWHAT
YES NO SOMEWHAT
The learner will be able to describe the body shape changes commonly associated with HIV infection
and some of the strategies related to treating these changes.
The learner will be able to discuss the newest antiretroviral medications indicated for the treatment of
HIV-1.
The learner will be able to explain the changes in the The US Department of Health and Human
Services newest guidelines for the use of antiretroviral agents in HIV-1-infected adults and
adolescents.
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American Correctional Association Winter Conference
Grapevine, TX
January 11-16, 2008
Visit:http://www.aca.org/conferences/Winter08/
Conference on Retroviruses and Opportunistic Infections (CROI)
Boston MA
February 3 - 6, 2008
Visit:http://www.retroconference.org/2008/
Infectious Diseases: Adult Issues in the Outpatient and Inpatient Settings
Sarasota, FL
March 10-14, 2008
Visit: http://www.ams4cme.com
2nd Annual Academic and Health Policy Conference on Correctional
Health
Boston Marriott, Quincy, MA
March 27-28, 2008
Visit:http://www.umassmed.edu/Correctional_Health_Conf/index.aspx
Rapid HIV Testing & Diagnosing Acute HIV Infection
Satellite Videoconference & Webcast
April 18, 2008
12:30-2:30 p.m. (ET)
CME's & Nursing credits, No Fees
Visit: www.amc.edu/hivconference
(518) 262-4674
ybarraj@mail.amc.edu
Updates in Correctional Health Care
San Antonio, TX
May 17-20, 2008
Viist: http://www.ncchc.org/education
/index.html
2008 HIV Prevention Leadership Summit
Detroit, MI
June 11-14, 2007
Visit:http://nmac.org/conferencestrainings/HPLS/
SAVE THE DATES
